1Cella M, Scheidegger D,Palmer LK, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cells stimulatory capacity: T-T help via APC activation [J]. J Exp Med,1996, 184:747.
2Sauter B,Albert ML,Francisco L,et al. Consequences of cell death:exposure to necrotic tumor cells,but not primary tissue cells, induces the maturation of immunostimulatory dendritic cells[J]. J Exp Med,2000,191(3): 423.
3Numasaki M, Lotze MT, Tahara H, et al. Interleukin 17gene transfection into murine fibrosarcoma cell line MCA205 increase tumorigenicity correlated with enhanced tumor microvascularity [J]. J Immunotherapy,1997, 20:399.
4Nair SK,Hull S,Coleman D,et al. Induction of carcinoembryonic antigen (CEA) - specific cytotoxic T - lymphocyte response in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA[J
5Kugler A,Stuhler G,Walden P,et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids[J]. Nat Med,2000,6(3):332.
6Ranieri E,Kierstead LS,Zarour H,et al. Dendritic cell peptide cancer vaccines:clinical responsiveness and epitope spreading[J]. Immunol Invest,2000,29(2): 121.
7Mule JJ. Tumor vaccine strategies that employ dendritic cells and tumor lysates: exprimental and clinical studies[J]. Immunol Invest,2000,29(2) : 127.
8Robert K,Detlef S,Petra R,et al. Noncovalent association with stress protein facilitates cross-priming of CD8+ T cells to tumor cell antigens by dendritic cells[J]. J Immunol,2002,168: 108.
9Ronan F,Richard T. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine[J]. Transfusion Medicine Review, 2001,15 (4): 292.
10Zhang W,He L,Yuan Z,et al. Enhanced therapeatic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lyrmphotactin [J]. Hum Gene Ther,1999,10(7):1151.
